# Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

> **NCT06766461** · PHASE4 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 980 (estimated)

## Conditions studied

- Sepsis - to Reduce Mortality in the Intensive Care Unit
- Sepsis
- Septic Shock

## Interventions

- **DRUG:** Double dosing of beta-lactam antibiotic

## Key facts

- **NCT ID:** NCT06766461
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 980 (ESTIMATED)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06766461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06766461, "Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06766461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*